JP2020522473A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522473A5 JP2020522473A5 JP2019564917A JP2019564917A JP2020522473A5 JP 2020522473 A5 JP2020522473 A5 JP 2020522473A5 JP 2019564917 A JP2019564917 A JP 2019564917A JP 2019564917 A JP2019564917 A JP 2019564917A JP 2020522473 A5 JP2020522473 A5 JP 2020522473A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable domain
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023172090A JP2024012297A (ja) | 2017-05-23 | 2023-10-03 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510173P | 2017-05-23 | 2017-05-23 | |
| US62/510,173 | 2017-05-23 | ||
| US201762539419P | 2017-07-31 | 2017-07-31 | |
| US201762539416P | 2017-07-31 | 2017-07-31 | |
| US201762539396P | 2017-07-31 | 2017-07-31 | |
| US62/539,396 | 2017-07-31 | ||
| US62/539,419 | 2017-07-31 | ||
| US62/539,416 | 2017-07-31 | ||
| US201762546292P | 2017-08-16 | 2017-08-16 | |
| US201762546296P | 2017-08-16 | 2017-08-16 | |
| US62/546,292 | 2017-08-16 | ||
| US62/546,296 | 2017-08-16 | ||
| US201762552146P | 2017-08-30 | 2017-08-30 | |
| US62/552,146 | 2017-08-30 | ||
| PCT/US2018/034223 WO2018217947A1 (en) | 2017-05-23 | 2018-05-23 | A protein binding nkg2d, cd16 and a tumor-associated antigen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023172090A Division JP2024012297A (ja) | 2017-05-23 | 2023-10-03 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522473A JP2020522473A (ja) | 2020-07-30 |
| JP2020522473A5 true JP2020522473A5 (2) | 2021-07-26 |
Family
ID=64395887
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564917A Withdrawn JP2020522473A (ja) | 2017-05-23 | 2018-05-23 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
| JP2023172090A Pending JP2024012297A (ja) | 2017-05-23 | 2023-10-03 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023172090A Pending JP2024012297A (ja) | 2017-05-23 | 2023-10-03 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200157227A1 (2) |
| EP (1) | EP3630169A4 (2) |
| JP (2) | JP2020522473A (2) |
| KR (1) | KR20200010430A (2) |
| CN (1) | CN111278455A (2) |
| AU (1) | AU2018271930B2 (2) |
| BR (1) | BR112019024632A2 (2) |
| CA (1) | CA3064714A1 (2) |
| IL (1) | IL270803B1 (2) |
| MX (1) | MX2019014000A (2) |
| WO (1) | WO2018217947A1 (2) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| JP7848114B2 (ja) * | 2019-10-12 | 2026-04-20 | バイオ－セラ ソリューションズ リミテッド | 抗ｃｄ２０抗体製剤及びｃｄ２０陽性疾患の治療のための抗ｃｄ２０抗体の使用 |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| CN114057875B (zh) * | 2020-07-31 | 2023-05-05 | 北京市神经外科研究所 | 抗cd133的单链抗体及其在制备治疗肿瘤的药物中的用途 |
| CN116368154A (zh) * | 2020-10-08 | 2023-06-30 | 阿菲姆德股份有限公司 | 三特异性结合剂 |
| PL244438B1 (pl) * | 2020-12-28 | 2024-01-29 | Inst Biochemii I Biofizyki Polskiej Akademii Nauk | Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| WO2023274183A1 (zh) * | 2021-06-29 | 2023-01-05 | 江苏先声药业有限公司 | Cd16抗体及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040038339A1 (en) * | 2000-03-24 | 2004-02-26 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| DE10261223A1 (de) * | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen |
| DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| AU2008337517B2 (en) * | 2007-12-14 | 2014-06-26 | Novo Nordisk A/S | Antibodies against human NKG2D and uses thereof |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| US9527926B2 (en) * | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| JP2013537416A (ja) * | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法 |
| UY33707A (es) * | 2010-11-04 | 2012-05-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| ES2758994T3 (es) * | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| BR112014010580B1 (pt) * | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| HUE033245T2 (hu) * | 2011-12-19 | 2017-11-28 | Synimmune Gmbh | Bispecifikus ellenanyag molekula |
| AU2013289883B2 (en) * | 2012-07-13 | 2018-11-01 | Zymeworks Bc Inc. | Bispecific asymmetric heterodimers comprising anti-CD3 constructs |
| HUE042040T2 (hu) * | 2012-09-27 | 2019-06-28 | Merus Nv | Bispecifikus IGG antitestek mint T-sejt kapcsolók |
| SMT202100464T1 (it) * | 2013-03-14 | 2021-11-12 | Macrogenics Inc | Molecole bispecifiche che sono immunoreattive con cellule effettrici immunitarie che esprimono un recettore di attivazione |
| CN105722859B (zh) * | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| RU2016132863A (ru) * | 2014-01-15 | 2018-02-20 | Займворкс Инк. | БИСПЕЦИФИЧЕСКИЕ CD3 и CD19 АНТИГЕНСВЯЗЫВАЮЩИЕ КОНСТРУКЦИИ |
| EP4050026A1 (en) * | 2014-04-01 | 2022-08-31 | Adimab, LLC | Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody |
| EA035419B9 (ru) * | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| WO2015197598A2 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Multispecific antigen binding proteins |
| WO2016122701A1 (en) * | 2015-01-26 | 2016-08-04 | Macrogenics, Inc. | Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof |
| WO2016146702A1 (en) * | 2015-03-16 | 2016-09-22 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Trispecific binding molecules for treating hbv infection and associated conditions |
| DK3313876T3 (da) * | 2015-06-23 | 2025-04-22 | Innate Pharma | Multispecifikke antigenbindende proteiner |
| EP3322735A4 (en) * | 2015-07-15 | 2019-03-13 | Zymeworks Inc. | ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS |
| US20180327499A1 (en) * | 2015-11-13 | 2018-11-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| AU2018219887B2 (en) * | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
-
2018
- 2018-05-23 IL IL270803A patent/IL270803B1/en unknown
- 2018-05-23 KR KR1020197037754A patent/KR20200010430A/ko not_active Ceased
- 2018-05-23 US US16/615,261 patent/US20200157227A1/en active Pending
- 2018-05-23 AU AU2018271930A patent/AU2018271930B2/en active Active
- 2018-05-23 CA CA3064714A patent/CA3064714A1/en active Pending
- 2018-05-23 JP JP2019564917A patent/JP2020522473A/ja not_active Withdrawn
- 2018-05-23 EP EP18806934.8A patent/EP3630169A4/en active Pending
- 2018-05-23 MX MX2019014000A patent/MX2019014000A/es unknown
- 2018-05-23 CN CN201880051763.5A patent/CN111278455A/zh active Pending
- 2018-05-23 WO PCT/US2018/034223 patent/WO2018217947A1/en not_active Ceased
- 2018-05-23 BR BR112019024632-0A patent/BR112019024632A2/pt unknown
-
2023
- 2023-10-03 JP JP2023172090A patent/JP2024012297A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522473A5 (2) | ||
| JP2020521448A5 (2) | ||
| JP2021098732A5 (2) | ||
| JP2021534096A5 (2) | ||
| JP2021098733A5 (2) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021035388A5 (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| JP2020522474A5 (2) | ||
| JP2021512630A5 (2) | ||
| JP2022515318A5 (2) | ||
| JP2021523140A5 (2) | ||
| JP2020103301A5 (2) | ||
| JP2021522162A5 (2) | ||
| RU2007145419A (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| JP2020508997A5 (2) | ||
| RU2019128134A (ru) | Антитело против gprc5d и молекула, содержащая антитело | |
| JP2023538945A5 (2) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2019536430A5 (2) | ||
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| JP2021533169A5 (2) | ||
| CN116396386A (zh) | Cd3抗体及其药物用途 | |
| JP2020507328A5 (2) | ||
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| RU2019128204A (ru) | Белки, связывающиеся с psma, nkg2d и cd16 |